Prosecution Insights
Prosecution Insights
9 pending office actions • 8 clients • 9 examiners • 8 art units • 0 of 9 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (33%) |
| §102 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| No statute on record | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHHAY, BONIRATH | 1 | 100.0% | +0.0% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| SAMSELL, RILLA MARIE | 1 | 71.4% | +0.0% |
| SALVOZA, M FRANCO G | 1 | 69.0% | +29.4% |
| HUMPHREY, LOUISE WANG ZHIYING | 1 | 47.1% | +30.0% |
| MOORE, SUSANNA | 1 | 68.1% | +31.8% |
| TRAN, CHRISTINA L | 1 | 46.8% | +51.2% |
| ORWIG, KEVIN S | 1 | 25.3% | +39.6% |
| WOZNICKI, JACQUELINE | 1 | 49.7% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17336491 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN | ORWIG, KEVIN S | 89d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17413973 | RECOMBINANT VECTORS FOR THE LONG TERM TREATMENT OF MUCCHOPOLYSACHARIDOSIS | TRAN, CHRISTINA L | 372d overdue |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | SALVOZA, M FRANCO G | 155d overdue |
| 17834232 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY | HUMPHREY, LOUISE WANG ZHIYING | 146d overdue |
| 17609452 | USE OF CO-CRYSTALS OF TRAMADOL AND CELECOXIB FOR TREATING PAIN WHILE REDUCING THE ABUSE LIABILITY OF TRAMADOL | MOORE, SUSANNA | 100d overdue |
| 17336491 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN | ORWIG, KEVIN S | 89d overdue |
| 16632453 | STENTED VALVE | WOZNICKI, JACQUELINE | 85d |
| Client (Assignee) | Pending OAs |
|---|---|
| ESTEVE PHARMACEUTICALS, S.A. | 2 |
| Italfarmaco | 1 |
| Novartis | 1 |
| Vernalis (R&D) Ltd. | 1 |
| SEMENTIS LIMITED | 1 |
| MERZ PHARMA GMBH & CO. KGAA | 1 |
| UAB | 1 |
| NATIONAL UNIVERSITY OF IRELAND, GALWAY | 1 |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1645 | 1 |
| 1625 | 1 |
| 1672 | 1 |
| 1657 | 1 |
| 1637 | 1 |
| 3991 | 1 |
| 3774 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18555103 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | Italfarmaco Spa | CHHAY, BONIRATH | 1645 | Other | Non-Final OA | 13d | Pending | Oct 12, 2023 |
| 18551033 | NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS | Novartis AG | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | 34d | Pending | Sep 18, 2023 |
| 18262231 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Vernalis (R&D) Ltd. | SAMSELL, RILLA MARIE | 1624 | DPOther | Final Rejection | 70d | Pending | Jul 20, 2023 |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | Sementis Limited | SALVOZA, M FRANCO G | 1672 | §103 | Final Rejection | 155d overdue | Pending | May 15, 2023 |
| 17834232 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY | Merz Pharma GmbH & Co. Kgaa | HUMPHREY, LOUISE WANG ZHIYING | 1657 | §103 | Final Rejection | 146d overdue | Pending | Jun 07, 2022 |
| 17609452 | USE OF CO-CRYSTALS OF TRAMADOL AND CELECOXIB FOR TREATING PAIN WHILE REDUCING THE ABUSE LIABILITY OF TRAMADOL | Esteve Pharmaceuticals, S.A. | MOORE, SUSANNA | 1624 | Other | Non-Final OA | 100d overdue | Pending | Nov 08, 2021 |
| 17413973 | RECOMBINANT VECTORS FOR THE LONG TERM TREATMENT OF MUCCHOPOLYSACHARIDOSIS | UNIVERSITA AUTÒNOMA DE BARCELONA | TRAN, CHRISTINA L | 1637 | §103 | Final Rejection | 372d overdue | Pending | Jun 15, 2021 |
| 17336491 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN | Esteve Pharmaceuticals, S.A. | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | 89d overdue | Pending | Jun 02, 2021 |
| 16632453 | STENTED VALVE | National University Of Ireland, Galway | WOZNICKI, JACQUELINE | 3774 | §112 | Non-Final OA | 85d | Pending | Jan 20, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial